Opendata, web and dolomites

UNNAMEd-2 SIGNED

Unraveling the conceptional novel ADAM17 regulation by PP2A in metastasis formation.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 UNNAMEd-2 project word cloud

Explore the words cloud of the UNNAMEd-2 project. It provides you a very rough idea of what is the project "UNNAMEd-2" about.

therapeutic    release    multiple    therapeutics    vivo    urgently    metastasis    receptor    ligand    vitro    deaths    negatively    tumour    interaction    thereby    kveiborg    protein    therapies    choices    regulator    models    patients    depletion    hypothesize    adam    ligands    showed    egfr    cancers    metalloproteinase    mechanism    spectrometry    silac    pool    collaborators    group    around    strategy    urgent    treatments    disintegrin    almost    regulation    regulates    crispr    90    signals    failed    coupled    interplay    enzyme    expression    zebrafish    mechanisms    representing    binding    mass    treatment    drugs    clinical    cells    phosphatase    binds    clinically    unravel    expand    functional    mouse    hypothesis    axis    epidermal    showing    mutagenesis    pp2a    treat    colon    anti    understand    spread    survival    discoveries    dr    cas9    unpublished    17    molecular    mutants    data    resistance    significantly    pave    cancer    negative    reduce    screening    adam17    first    inhibits    patient    aberrant    functionally   

Project "UNNAMEd-2" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

Around 90% of all cancer-related deaths are due to metastasis. Understanding the process of cancer metastasis is therefore of urgent need to develop new treatments. Aberrant expression of the epidermal growth factor receptor (EGFR), or increased availability of its ligands promote tumour survival and metastasis in multiple cancers. As a result, several anti-EGFR therapeutics are in clinical use, but almost all patients will develop resistance against the treatment. Another strategy to treat EGFR driven cancers is to reduce the pool of available EGFR ligands. The crucial enzyme in EGFR ligand release is A Disintegrin And Metalloproteinase (ADAM) 17. I have unpublished data showing that depletion of ADAM17 significantly inhibits colon cancer growth and metastasis in vivo. However, anti-ADAM17 therapies have failed clinically and thus, we urgently need to understand the regulation of ADAM17. Recent discoveries by Dr. Kveiborg’s group, and collaborators showed that the protein phosphatase PP2A binds to ADAM17, and negatively regulates EGFR ligand release, thereby representing the first known negative regulator for ADAM17. Based on these novel findings, I hypothesize that the PP2A-ADAM17-EGFR axis has the ability to control cancer metastasis. To test this hypothesis, I aim to characterize the functional impact of the PP2A-ADAM17 interaction in cancer spread by creating ADAM17 mutants with different PP2A binding properties in colon cancer cells using CRISPR/Cas9 and functionally evaluate these cells in vitro and in zebrafish and mouse models. Moreover, I aim to unravel the molecular mechanisms of the interplay; applying SILAC coupled mass spectrometry and mutagenesis screening, to evaluate the mechanism by which PP2A affects ADAM17, and the signals involved in PP2A binding. This work will pave the way for the development of novel anti-cancer drugs and thereby expand the therapeutic choices for EGFR driven cancers and improve the patient survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UNNAMED-2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UNNAMED-2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiquidEff (2019)

LiquidEff: Algebraic Foundations for Liquid Effects

Read More  

EcoSpy (2018)

Leveraging the potential of historical spy satellite photography for ecology and conservation

Read More  

Cata-rotors (2019)

Visualising age- and cataract-related changed within cell membranes of human eye lens using molecular rotors

Read More